Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exendin (9-39) in Post-Bariatric Hypoglycemia
NCT02996812Phase 1Completed
- Start
- Apr 2015
- Primary completion
- Aug 2016
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of exendin 9-39 in post-bariatric hypoglycemia (PBH) (4 arms). Primary endpoint: Treatment effect on plasma glucose. Started Apr 2015; status: completed.
02
Drugs
exendin 9-39
03
Conditions
post-bariatric hypoglycemia (PBH)
Beyond the preview
Go deeper on NCT02996812.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02996812.